<DOC>
	<DOCNO>NCT00006105</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemoprotective drug , amifostine , may protect normal cell side effect chemotherapy . PURPOSE : Phase II trial study effectiveness combine gemcitabine , cisplatin , amifostine follow surgery treat patient locally advanced bladder cancer .</brief_summary>
	<brief_title>Gemcitabine , Cisplatin , Amifostine Following Surgery Treating Patients With Locally Advanced Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity adjuvant gemcitabine cisplatin amifostine cytoprotection patient completely resect locally advanced bladder cancer . - Compare recurrence rate patient treat regimen historical control patient cystectomy perform surgeon . OUTLINE : Patients receive gemcitabine IV 30 minute day 1 , 8 , 15 , cisplatin IV 60 minute amifostine IV 15 minute day 1 . Treatment continue every 28 day total 4 course absence disease progression unacceptable toxicity . Patients follow every 6 month . PROJECTED ACCRUAL : A total 19-42 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Completely resect locally advanced bladder cancer T24 , N02 Post radical cystectomy gross residual disease No evidence metastasis CT chest , abdomen , pelvis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 Life expectancy : At least 12 week Hematopoietic : WBC least 3,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL ( transfusion allow ) Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST ALT great 3 time ULN Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 50 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception 3 month study participation No active infection No serious concurrent systemic disorder would preclude study participation No metastatic cancer past 5 year PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy except contraceptive replacement steroid Radiotherapy : No concurrent radiotherapy Surgery : See Disease Characteristics At least 4 8 week since radical cystectomy Other : No concurrent experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
</DOC>